Edition:
United States

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

184.35USD
3:59pm EST
Change (% chg)

$1.40 (+0.77%)
Prev Close
$182.95
Open
$184.70
Day's High
$186.90
Day's Low
$182.00
Volume
248,925
Avg. Vol
280,478
52-wk High
$222.00
52-wk Low
$61.00

Chart for

About

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical... (more)

Overall

Beta: 2.07
Market Cap(Mil.): $8,384.77
Shares Outstanding(Mil.): 45.83
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Bluebird Bio Prices Public Offering Of 3.2 Mln Shares At $185/Share

* BLUEBIRD BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Dec 12 2017

BRIEF-Bluebird Bio Announces Proposed Public Offering Of Common Stock

* BLUEBIRD BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Dec 11 2017

BRIEF-bluebird bio And TC BioPharm Announce Strategic Collaboration

* BLUEBIRD BIO AND TC BIOPHARM ANNOUNCE STRATEGIC COLLABORATION TO RESEARCH AND DEVELOP GAMMA DELTA CAR T CELL PRODUCT CANDIDATES FOR CANCER IMMUNOTHERAPY

Dec 07 2017

BRIEF-Bluebird Bio Acquires Manufacturing Facility In North Carolina

* BLUEBIRD BIO ACQUIRES MANUFACTURING FACILITY IN NORTH CAROLINA AND EXECUTES MULTIPLE GLOBAL SUPPLY AGREEMENTS TO ENHANCE ABILITY TO DELIVER GENE THERAPIES TO PATIENTS Source text for Eikon: Further company coverage:

Nov 29 2017

BRIEF-Bluebird Bio says to receive $15 mln option exercise payment from Celgene​

* Bluebird Bio Inc - to receive $15 million option exercise payment from Celgene​

Sep 28 2017

BRIEF-Bluebird Bio appoints Mary Lynne Hedley, Ph.D. to board of directors

* Bluebird Bio appoints Mary Lynne Hedley, Ph.D. to board of directors Source text for Eikon: Further company coverage:

Sep 20 2017

BRIEF-Bluebird Bio Q2 net loss per share $1.73

* Bluebird Bio reports second quarter 2017 financial results and recent operational progress

Aug 02 2017

BRIEF-Bluebird Bio announces pricing of public offering of common stock

* Bluebird Bio announces pricing of public offering of common stock

Jun 27 2017

BRIEF-Bluebird bio reports updated clinical data from starbeam study

* bluebird bio Inc says on June 26, co reported updated clinical data from starbeam study clinical study of its lenti-d product candidate - sec filing

Jun 26 2017

Earnings vs. Estimates